Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Orphan Drugs Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Oncology
  • 1.3.3 Gastrointestinal
  • 1.3.4 Pulmonary
  • 1.3.5 Neurology
  • 1.3.6 Hematology
  • 1.3.7 Cardio-vascular
  • 1.3.8 Metabolic disorders
  • 1.3.9 Endocrinology
  • 1.3.10 Infectious diseases
  • 1.3.11 Others
• 1.4 Market Segment by Application
  • 1.4.1 Global Orphan Drugs Market Share by Application (2019-2025)
  • 1.4.2 Hospital Pharmacies
  • 1.4.3 Speciality Pharmacies
  • 1.4.4 Retail pharmacies
  • 1.4.5 Others
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Orphan Drugs Market Size
  • 2.1.1 Global Orphan Drugs Revenue 2014-2025
  • 2.1.2 Global Orphan Drugs Sales 2014-2025
• 2.2 Orphan Drugs Growth Rate by Regions
  • 2.2.1 Global Orphan Drugs Sales by Regions 2014-2019
  • 2.2.2 Global Orphan Drugs Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Orphan Drugs Sales by Manufacturers
  • 3.1.1 Orphan Drugs Sales by Manufacturers 2014-2019
  • 3.1.2 Orphan Drugs Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Orphan Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Orphan Drugs Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Orphan Drugs Market Concentration Ratio (CR5 and HHI)
• 3.3 Orphan Drugs Price by Manufacturers
• 3.4 Key Manufacturers Orphan Drugs Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Orphan Drugs Market
• 3.6 Key Manufacturers Orphan Drugs Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Oncology Sales and Revenue (2014-2019)
  • 4.1.2 Gastrointestinal Sales and Revenue (2014-2019)
  • 4.1.3 Pulmonary Sales and Revenue (2014-2019)
  • 4.1.4 Neurology Sales and Revenue (2014-2019)
  • 4.1.5 Hematology Sales and Revenue (2014-2019)
  • 4.1.6 Cardio-vascular Sales and Revenue (2014-2019)
  • 4.1.7 Metabolic disorders Sales and Revenue (2014-2019)
  • 4.1.8 Endocrinology Sales and Revenue (2014-2019)
  • 4.1.9 Infectious diseases Sales and Revenue (2014-2019)
  • 4.1.10 Others Sales and Revenue (2014-2019)
• 4.2 Global Orphan Drugs Sales Market Share by Type
• 4.3 Global Orphan Drugs Revenue Market Share by Type
• 4.4 Orphan Drugs Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Orphan Drugs Sales by Application

6 United States

• 6.1 United States Orphan Drugs Breakdown Data by Company
• 6.2 United States Orphan Drugs Breakdown Data by Type
• 6.3 United States Orphan Drugs Breakdown Data by Application

7 European Union

• 7.1 European Union Orphan Drugs Breakdown Data by Company
• 7.2 European Union Orphan Drugs Breakdown Data by Type
• 7.3 European Union Orphan Drugs Breakdown Data by Application

8 China

• 8.1 China Orphan Drugs Breakdown Data by Company
• 8.2 China Orphan Drugs Breakdown Data by Type
• 8.3 China Orphan Drugs Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Orphan Drugs Breakdown Data by Company
• 9.2 Rest of World Orphan Drugs Breakdown Data by Type
• 9.3 Rest of World Orphan Drugs Breakdown Data by Application
• 9.4 Rest of World Orphan Drugs Breakdown Data by Countries
  • 9.4.1 Rest of World Orphan Drugs Sales by Countries
  • 9.4.2 Rest of World Orphan Drugs Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Novartis
  • 10.1.1 Novartis Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Orphan Drugs
  • 10.1.4 Orphan Drugs Product Introduction
  • 10.1.5 Novartis Recent Development
• 10.2 Bristol-Myers Squibb
  • 10.2.1 Bristol-Myers Squibb Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Orphan Drugs
  • 10.2.4 Orphan Drugs Product Introduction
  • 10.2.5 Bristol-Myers Squibb Recent Development
• 10.3 Celgene
  • 10.3.1 Celgene Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Orphan Drugs
  • 10.3.4 Orphan Drugs Product Introduction
  • 10.3.5 Celgene Recent Development
• 10.4 Roche
  • 10.4.1 Roche Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Orphan Drugs
  • 10.4.4 Orphan Drugs Product Introduction
  • 10.4.5 Roche Recent Development
• 10.5 Pfizer
  • 10.5.1 Pfizer Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Orphan Drugs
  • 10.5.4 Orphan Drugs Product Introduction
  • 10.5.5 Pfizer Recent Development
• 10.6 Sanofi
  • 10.6.1 Sanofi Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Orphan Drugs
  • 10.6.4 Orphan Drugs Product Introduction
  • 10.6.5 Sanofi Recent Development
• 10.7 Alexion Pharmaceuticals
  • 10.7.1 Alexion Pharmaceuticals Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Orphan Drugs
  • 10.7.4 Orphan Drugs Product Introduction
  • 10.7.5 Alexion Pharmaceuticals Recent Development
• 10.8 Eli Lilly
  • 10.8.1 Eli Lilly Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Orphan Drugs
  • 10.8.4 Orphan Drugs Product Introduction
  • 10.8.5 Eli Lilly Recent Development
• 10.9 Novo Nordisk
  • 10.9.1 Novo Nordisk Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Orphan Drugs
  • 10.9.4 Orphan Drugs Product Introduction
  • 10.9.5 Novo Nordisk Recent Development
• 10.10 AstraZeneca
  • 10.10.1 AstraZeneca Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Orphan Drugs
  • 10.10.4 Orphan Drugs Product Introduction
  • 10.10.5 AstraZeneca Recent Development
• 10.11 Eisai
• 10.12 Daiichi Sankyo
• 10.13 Bayer
• 10.14 GlaxoSmithKline
• 10.15 Merck
• 10.16 Johnson & Johnson
• 10.17 Biogen
• 10.18 Shire
• 10.19 Amgen

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Orphan Drugs Sales Channels
  • 11.2.2 Orphan Drugs Distributors
• 11.3 Orphan Drugs Customers

12 Market Forecast

• 12.1 Global Orphan Drugs Sales and Revenue Forecast 2019-2025
• 12.2 Global Orphan Drugs Sales Forecast by Type
• 12.3 Global Orphan Drugs Sales Forecast by Application
• 12.4 Orphan Drugs Forecast by Regions
  • 12.4.1 Global Orphan Drugs Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Orphan Drugs Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.
High unmet needs are one of the primary drivers of market growth. The need for the development of effective drugs with lesser side-effects is rapidly rising in the market.
Moreover, the initiatives from the governments of various countries across the globe towards R&D activities and numerous marketing approvals of these drugs have also influenced the orphan drugs market growth. Furthermore, the rising occurrences of rare diseases with the mounting awareness among the population and larger life expectancy numbers have accelerated the global orphan drug market to grow higher.
In 2019, the market size of Orphan Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Orphan Drugs.

This report studies the global market size of Orphan Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Orphan Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Novartis
Bristol-Myers Squibb
Celgene
Roche
Pfizer
Sanofi
Alexion Pharmaceuticals
Eli Lilly
Novo Nordisk
AstraZeneca
Eisai
Daiichi Sankyo
Bayer
GlaxoSmithKline
Merck
Johnson & Johnson
Biogen
Shire
Amgen

Market Segment by Product Type
Oncology
Gastrointestinal
Pulmonary
Neurology
Hematology
Cardio-vascular
Metabolic disorders
Endocrinology
Infectious diseases
Others

Market Segment by Application
Hospital Pharmacies
Speciality Pharmacies
Retail pharmacies
Others

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Orphan Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Orphan Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Orphan Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025